About

Service

Advantage

Quarkmed Dynamics

Human Resources

Mail System

CTMS System

中EN

Quarkmed Dynamics

Quarkmed will keep moving forward, paying attention to hot topics in the industry, discussing the latest developments in the industry, and working with enterprises to promote new progress in medicine.
Partial Cooperative ClientsQuarkmed NewsTeam Style
Home>Quarkmed Dynamics
232026-01

Actinium-225: The "Alpha Warrior" Ushering in a New Era of Radiopharmaceutical Therapy

An Introduction to the Actinium-225 Nuclide and the ACTION-1 StudyAlpha-emitting radiopharmaceuticals utilize radionuclides that emit alpha particles, such as Radium-223 ([²²³Ra]), Actinium-225 ([²²⁵Ac]), Thorium-227 ([²²⁷Th]), Astatine-211 ([²¹¹At])...

302025-09

Happy Hour - Gathering at EANM 2025

As Europes largest nuclear medicine academic event, EANM brings together experts, scholars, and industry partners from around the world annually to discuss the latest developments and future trends in...

302025-09

Quarkmed has won the title of "Best Partner" / "Best Partner Award"

Recently, Quarkmed was awarded the "Best Partner" award by Jingxin Pharmaceutical for its outstanding professional performance and efficient project execution in the Phase III clinical trial collabora...

302025-09

Quarkmed is invited to attend the Hangzhou Biomedicine Industry-Finance Summit

On April 29th, the "Hangzhou Biomedicine Industry-Finance Summit," hosted by Tailong Investment and co-supported by Hangzhou Industrial Investment Group, High-tech Financial Investment Group, and Tig...

302025-09

Exploring Innovative Paths in Radiopharmaceuticals: Quarkmed Joins Forces with Industry Chain to Bui

2025 Future XDC New Drug ConferenceFrom April 17th to 18th, 2025, the "Future XDC New Drug Conference" was successfully held in Chengdu. At this interdisciplinary gathering, radiopharmaceuticals, as a...

302025-09

Great news! Quarkmed and Heyue Pharma have proudly made it to the TOP 10 list of clinical trial

In the wave of medical research and innovation, every collaboration signifies further exploration into unknown territories. Recently, Quarkmed and its subsidiary Heyue Medicine have ranked among the t...

302025-09

The VIQU Nuclear Medicine CXO Alliance Launch Ceremony and "Comprehensive Exploration: In-depth Anal

On the afternoon of November 28, 2024, with the countdown on the large screen starting, the VIQU Nuclear Medicine CXO Alliance set sail brilliantly in Shanghai, marking a successful opening ceremony. ...

302025-09

Quarkmed Completes Series A Financing, Pioneering a New Pattern in Multi-field Clinical Services!

Recently, Quarkmed successfully completed its Series A financing, securing tens of millions of RMB in funding led by Tai Kun Fund, with follow-on investments from Mint Angel Fund and Guoshun Jianheng ...

182023-07

A meeting for phase III clinical trial researchers for 18F-NaF injection was held successfully

On September 30, 2020, a meeting for phase III clinical trial researchers for 18F-NaF injection was held successfully. The meeting is organized by Quarkmed and presided over by Huo Li, director of Nu...

182023-07

CRO Service for NICS to Assist IVF Technology Development

Recently, the clinical trial of Non-invasive Capacity Screening (NICS) developed by Yikon Genomics, an enterprise dedicated to the development and application of single-cell whole-genome amplification...

123

Contact Us

010-86469979

Address：Ping An Fortune Center, Lize Financial Business District of Beijing

Follow the Wechat official account

Follow the Wechat official account